期刊
TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY
卷 21, 期 118, 页码 71-86出版社
GAKUSHIN PUBL CO
DOI: 10.4052/tigg.21.71
关键词
glycoprotein; N-glycan; processing; insect cell; engineering; therapeutic
资金
- NSF [BES 9905171, BES 9814100]
- NIH [IR01GM067935, 5R01GM067935-03]
Many of the most valuable recombinant DNA products, including monoclonal antibodies, are secreted glycoproteins, which contain N-glycans. The biochemical nature of these attached glycans depends on the characteristics of the host cell used, the protein synthesized, and the culture environment. The capacity to produce functional glycoproteins with desired glycosylation patterns depends on the presence of proper cellular enzymatic machinery required for the processing of N-glycans. It is well recongnized that expression of therapeutic proteins using insect cells in combination with the baculovirus-expression system has potential advantages in terms of the ease of large scale, low cost production of heterologous glycoproteins. However, the glycoforms expressed in several commonly used insect cell lines are markedly different from those expressed in human cells. As N-glycans often affect the in vivo biological activity, pharmacokinetics, and several other properties of glycoproteins, the glycoforms produced in this system have become a major concern in the last few years. Accordingly, considerable effort has been invested in the past decade in order to gain a better understanding of the processing of N-glycans in insect cells that generate different glycoforms, and also to overcome the bottlenecks to producing glycoproteins with humanized N-glycans that are more suitable for therapeutic use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据